What meningococcal vaccination schedule should be given to an infant (age 2 months to 23 months), including MenACWY (meningococcal A, C, W, Y) and MenB (meningococcal B) recommendations and high‑risk considerations?

Meningococcal Vaccination for Infants (2-23 Months)

Routine meningococcal vaccination is NOT recommended for healthy infants aged 2-23 months in the United States—these vaccines are reserved exclusively for high-risk infants with specific medical conditions or outbreak exposure 1.

Standard Recommendation: No Routine Vaccination

Healthy infants do not receive meningococcal vaccines as part of the routine immunization schedule. The vaccines are only indicated when specific risk factors are present.

High-Risk Indications for MenACWY Vaccination

Vaccinate infants aged 2-23 months with MenACWY ONLY if they have:

• Complement deficiencies (C3, C5-C9, properdin, factor D, factor H)
• Functional or anatomic asplenia (including sickle cell disease)
• HIV infection
• Travel to or residence in hyperendemic/epidemic areas (particularly sub-Saharan Africa)
• Exposure during a community outbreak of vaccine-preventable serogroups

MenACWY Vaccine Schedules for High-Risk Infants

MenACWY-CRM (Menveo) - Preferred for Infants Starting at 2 Months

Age-specific dosing 1:

• Starting at 2 months: 4-dose series at 2,4,6, and 12 months
• Starting at 3-6 months: Catch-up with doses every 8 weeks until age ≥7 months, then one dose at ≥7 months, followed by final dose ≥12 weeks later and after the 1st birthday
• Starting at 7-23 months: 2-dose series with second dose ≥12 weeks after first dose and after the 1st birthday

MenACWY-D (Menactra) - Only for Infants ≥9 Months

Critical timing restrictions 1:

• Licensed only for ages ≥9 months in this population
• 2-dose series: Doses separated by ≥12 weeks
• Must be given before or at the same time as DTaP to avoid immune interference
• CONTRAINDICATED before age 2 years in children with asplenia or HIV due to interference with pneumococcal conjugate vaccine (PCV) response—if used in these populations at any age, must wait ≥4 weeks after completing all PCV doses 1

MenACWY-TT (MenQuadfi)

• Not licensed for infants <2 years of age 1

MenB Vaccination: NOT Recommended for Infants

There are NO recommendations for MenB vaccines (MenB-FHbp [Trumenba] or MenB-4C [Bexsero]) in children aged 2-23 months 1. These vaccines are only licensed for ages 10-25 years.

Booster Doses for High-Risk Infants

If the infant remains at increased risk after primary vaccination 1:

• Age <7 years: Single booster dose 3 years after primary series, then every 5 years thereafter
• Age ≥7 years: Single booster dose 5 years after primary series, then every 5 years thereafter

Outbreak-Specific Vaccination

During community outbreaks of vaccine-preventable serogroups, the schedule follows the same age-based dosing as for high-risk conditions 1. Public health authorities will provide specific guidance.

Critical Clinical Pitfalls

1. Do not use MenACWY-D (Menactra) before 9 months of age—it is not licensed for younger infants
2. Never give MenACWY-D before age 2 years to infants with asplenia or HIV—this causes dangerous interference with PCV immune responses; wait until ≥4 weeks after PCV completion 1
3. Do not confuse high-risk vaccination with routine vaccination—parents may request these vaccines after hearing about adolescent recommendations, but they provide no benefit and are not indicated for healthy infants
4. MenB vaccines are not an option for this age group—despite covering serogroup B (which causes two-thirds of infant meningococcal disease), no MenB vaccine is approved or recommended for infants 1

Vaccine Selection Algorithm

For high-risk infants requiring vaccination:

1. Age 2-8 months: Use MenACWY-CRM (Menveo) only
2. Age 9-23 months with normal immune function: Either MenACWY-CRM or MenACWY-D
3. Age 9-23 months with asplenia or HIV: Use MenACWY-CRM only, OR delay MenACWY-D until age ≥2 years and ≥4 weeks post-PCV completion

The evidence consistently shows that while MenACWY vaccines are safe and immunogenic in infants 2, 3, the low incidence of disease in healthy infants does not justify routine vaccination 4, 5. The 2020 ACIP guidelines provide the definitive framework, restricting use to high-risk populations where the benefit clearly outweighs the burden of additional injections 1.